By Kelly Cloonan
Shares of OSR Holdings more than doubled after the company's Vaximm subsidiary announced final data from its Phase 2a clinical trial of VXM01 with avelumab, a drug combination aimed at treating recurrent glioblastoma.
The stock rose to $3.43 in regular trading Wednesday, helping partially offset its 70% fall over the past 12 months.
The immunotherapy developer said the trial found the VXM01-avelumab combination therapy was generally well-tolerated, with a 12% response rate for non-resected patients, or those who have not had their tumors removed by surgery. Those patients who responded to the treatment entered a partial remission, while 4% remained stable.
Tumor size decreased in patients who responded to the treatment, regardless of their baseline tumor size, showing the vaccine could be effective in patients with larger-sized tumors, very small tumors or early-stage cancer, the company said.
For patients in the cohort who had surgeries to remove their tumors, overall survival - or how long they survived after starting treatment - ranged from 2.2 to 46.5 months, demonstrating a need for additional studies on specific subgroups of GBM patients, the company said.
VXM01 is an oral vaccine designed to activate immune killer T-cells to attack tumor blood vessels, and in several tumor types, attack cancer cells directly.
"We are encouraged by these early results and the potential to improve outcomes for patients with this aggressive cancer. We remain committed to advancing VXM01 as a key therapeutic candidate for the treatment of glioblastoma, other cancers and other diseases where VXM01 may have positive impact on treatment outcomes," said Vaximm Chief Executive Constance Hoefer.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
March 26, 2025 12:05 ET (16:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Comments